Insulet insulin pump launched in Germany as company revenue booms
Photo | Courtesy of Insulet
Insulet's headquarters in Acton
Acton medical device firm Insulet Corp. has launched its flagship product, the Omnipod tubeless insulin device, in Germany a year after it received Food and Drug Administration approval for the device in the U.S.
The system will be reimbursable by German health insurance, according to a Monday press release from Insulet. The company intends to make the Omnipod available across the majority of European markets by the end of 2024.
In June, Insulet launched the Omnipod in the United Kingdom. The Omnipod system prevents users from needing to administer multiple daily injections.
In February, Insulet doubled its intellectual property with a pair of $25-million acquisitions.
The company reported $396.5 million in revenue for its second quarter, up 32.4%, or nearly $100 million, from its reported $299.4 million in the same period last year, according to an Aug. 8 press release from Insulet. Omnipod-related revenue made up $380.5 million for the second quarter.
WBJ Web Partners
Most Recent
Most Recent
0 Comments